ESC 2017
Here you will find the highlights of ESC 2017, held on August 26-30 in Barcelona, Spain.
If you cannot view the articles, click here
SYNTAX II: Better Stents, IVUS, FFR, or a Combination of All of Them to Catch Up with Surgery
In patients with 3-vessel disease, surgery obtained better outcomes than angioplasty, according to results from the SYNTAX and FREEDOM trials, which used first-generation drug-eluting stents. Even ...
In patients with 3-vessel disease, surgery obtained better outcomes than angioplasty, according to results from the SYNTAX and FREEDOM trials, which used first-generation drug-eluting stents. Even ...
FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels
It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients; in consequence, this study attempted to set a new target, one that appears almost impossible to ...
It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients; in consequence, this study attempted to set a new target, one that appears almost impossible to ...
DETO2X-AMI: Supplemental O2 Provides No Benefit for Patients with Suspected Infarction
According to this study simultaneously presented at the European Society of Cardiology Congress 2017 and published in the New England Journal of Medicine, routinely providing supplemental oxygen ...
According to this study simultaneously presented at the European Society of Cardiology Congress 2017 and published in the New England Journal of Medicine, routinely providing supplemental oxygen ...
COMPASS: A New Place for Rivaroxaban in Chronic Ischemic Heart Disease
Combining low doses of rivaroxaban and aspirin seems to be the best strategy for patients with stable chronic ischemic heart disease, according to this new study presented at the European Society ...
Combining low doses of rivaroxaban and aspirin seems to be the best strategy for patients with stable chronic ischemic heart disease, according to this new study presented at the European Society ...
CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events
This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with optimal medical therapy, according to a new study presented at ...
This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with optimal medical therapy, according to a new study presented at ...
VALIDATE-SWEDEHEART: bivalirudin seems to be losing ground
Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both efficacy (death and MI) and safety end points (bleeding) in ...
Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both efficacy (death and MI) and safety end points (bleeding) in ...
SPYRAL HTN-OFF MED: Renal Denervation Reloaded?
This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet , seems to give hope to all those that still believe in renal denervation. Interim ...
This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet , seems to give hope to all those that still believe in renal denervation. Interim ...
RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI
RE-DUAL PCI outcomes have been published by the New England Journal of Medicine along with their presentation at ESC 2017. The traditional triple anti-thrombotic scheme with ...
RE-DUAL PCI outcomes have been published by the New England Journal of Medicine along with their presentation at ESC 2017. The traditional triple anti-thrombotic scheme with ...